SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-050869
Filing Date
2021-10-14
Accepted
2021-10-14 17:10:41
Documents
13
Period of Report
2021-10-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nrix-8k_20211014.htm   iXBRL 8-K 41170
2 EX-99.1 nrix-ex991_6.htm EX-99.1 227991
  Complete submission text file 0001564590-21-050869.txt   415422

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrix-20211014.xsd EX-101.SCH 5681
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20211014_lab.xml EX-101.LAB 20078
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20211014_pre.xml EX-101.PRE 11931
6 EXTRACTED XBRL INSTANCE DOCUMENT nrix-8k_20211014_htm.xml XML 3682
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 211323955
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences